In a survey of U.S. adults with diabetes, about 13% who were prescribed medication said they did not take it as prescribed, and about 24% said they asked their doctors for a lower-cost medication.
In a longitudinal study of 21,531 patients, those in poor or intermediate health at age 75 years were more likely to use insulin than those in good health (29.4% and 27.5% versus 10.5%, respectively) and less likely to discontinue it during follow-up
Sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists had similar rates of other adverse events, including bone fracture, acute kidney injury, serious urinary tract infection, venous thromboembolism, and
Randomized trial participants with type 1 diabetes and mild-to-moderate diabetic kidney disease who received allopurinol or placebo had similar estimated glomerular filtration rates after three years.
Compared to young adults without diabetes, those with diabetes were more likely to have obesity, elevated lipids, or hypertension and were less likely to report being physically active or consuming a healthy diet.
Cardiovascular event rates similar between once-weekly exenatide and placebo in patients with type 2 diabetes
A limitation of the industry-funded randomized trial was the high rate of early discontinuation: 43.0% of patients on exenatide and 45.2% of those on placebo.
From 2000 to 2014, the age-standardized incidence of end-stage renal disease (ESRD) attributed to diabetes decreased from 260.2 to 173.9 per 100,000 diabetic population.
Risk of atrial fibrillation increased with worse glycemic control and renal complications. Among patients with normoalbuminuria, researchers found no excess risk of atrial fibrillation with an HbA1c less than 9.7% for men or 8.8% for women.
The review included 189 randomized controlled trials that compared glucagon-like peptide-1 receptor agonists or dipeptidyl peptidase-2 inhibitors with placebo or other diabetes drugs in patients with type 2 diabetes.
The hypoglycemia risk stratification tool is based on six variables: previous episodes of hypoglycemia-related hospital utilization, insulin use, sulfonylurea use, ED use in the previous year, chronic kidney disease stage, and age.